First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

PURPOSE: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This Phase I trial evaluated this ADC as a potential therapeutic for pretreated pati...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Starodub, Alexander N., Ocean, Allyson J., Shah, Manish A., Guarino, Michael J., Picozzi, Jr., Vincent J., Vahdat, Linda T., Thomas, Sajeve S., Govindan, Serengulam V., Maliakal, Pius P., Wegener, William A., Hamburger, Steven A., Sharkey, Robert M., Goldenberg, David M.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558321/
https://ncbi.nlm.nih.gov/pubmed/25944802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3321
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items